Cargando…

IL-17A and TNF-α inhibitors induce multiple molecular changes in psoriasis

Adalimumab and secukinumab are commonly used for moderate to severe psoriasis vulgaris (PV). Although distinct individual responses to and impaired effectiveness of these biological agents occur occasionally, little is known about the underlying reasons. Here, we report a proteomic analysis of psori...

Descripción completa

Detalles Bibliográficos
Autores principales: Dong, Qiang, Li, Dan, Xie, Bi Bo, Hu, Li Hua, Huang, Jia, Jia, Xiao Xiao, Tang, Yan Li, Liu, Gan Hong, Shen, Ning Ning, Yu, Xiao Bing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9723344/
https://www.ncbi.nlm.nih.gov/pubmed/36483564
http://dx.doi.org/10.3389/fimmu.2022.1015182
_version_ 1784844152564875264
author Dong, Qiang
Li, Dan
Xie, Bi Bo
Hu, Li Hua
Huang, Jia
Jia, Xiao Xiao
Tang, Yan Li
Liu, Gan Hong
Shen, Ning Ning
Yu, Xiao Bing
author_facet Dong, Qiang
Li, Dan
Xie, Bi Bo
Hu, Li Hua
Huang, Jia
Jia, Xiao Xiao
Tang, Yan Li
Liu, Gan Hong
Shen, Ning Ning
Yu, Xiao Bing
author_sort Dong, Qiang
collection PubMed
description Adalimumab and secukinumab are commonly used for moderate to severe psoriasis vulgaris (PV). Although distinct individual responses to and impaired effectiveness of these biological agents occur occasionally, little is known about the underlying reasons. Here, we report a proteomic analysis of psoriatic lesions from patients treated with these drugs using data-independent acquisition mass spectrometry (DIA-MS). Thousands of differentially expressed proteins (DEPs) changed over 12 weeks of treatment. Network analysis showed that DEPs could interact and induce transformation in matrix components, metabolic regulation, and immune response. The results of parallel reaction monitoring (PRM) analysis suggested that S100s, STAT1, KRT2, TYMP, SOD2, HSP90AB1, TFRC, and COL5A1 were the most significantly changed proteins in both groups. There was a positive association between the Psoriasis Area and Severity Index (PASI) score and three proteins (TFRC, IMPDH2, KRT2). Our study findings suggest that inhibition of IL-17A and TNF-α can induce changes in multiple molecules in psoriatic lesions and have an overlapping influence on the immune response and process through direct or indirect effects.
format Online
Article
Text
id pubmed-9723344
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-97233442022-12-07 IL-17A and TNF-α inhibitors induce multiple molecular changes in psoriasis Dong, Qiang Li, Dan Xie, Bi Bo Hu, Li Hua Huang, Jia Jia, Xiao Xiao Tang, Yan Li Liu, Gan Hong Shen, Ning Ning Yu, Xiao Bing Front Immunol Immunology Adalimumab and secukinumab are commonly used for moderate to severe psoriasis vulgaris (PV). Although distinct individual responses to and impaired effectiveness of these biological agents occur occasionally, little is known about the underlying reasons. Here, we report a proteomic analysis of psoriatic lesions from patients treated with these drugs using data-independent acquisition mass spectrometry (DIA-MS). Thousands of differentially expressed proteins (DEPs) changed over 12 weeks of treatment. Network analysis showed that DEPs could interact and induce transformation in matrix components, metabolic regulation, and immune response. The results of parallel reaction monitoring (PRM) analysis suggested that S100s, STAT1, KRT2, TYMP, SOD2, HSP90AB1, TFRC, and COL5A1 were the most significantly changed proteins in both groups. There was a positive association between the Psoriasis Area and Severity Index (PASI) score and three proteins (TFRC, IMPDH2, KRT2). Our study findings suggest that inhibition of IL-17A and TNF-α can induce changes in multiple molecules in psoriatic lesions and have an overlapping influence on the immune response and process through direct or indirect effects. Frontiers Media S.A. 2022-11-22 /pmc/articles/PMC9723344/ /pubmed/36483564 http://dx.doi.org/10.3389/fimmu.2022.1015182 Text en Copyright © 2022 Dong, Li, Xie, Hu, Huang, Jia, Tang, Liu, Shen and Yu https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Immunology
Dong, Qiang
Li, Dan
Xie, Bi Bo
Hu, Li Hua
Huang, Jia
Jia, Xiao Xiao
Tang, Yan Li
Liu, Gan Hong
Shen, Ning Ning
Yu, Xiao Bing
IL-17A and TNF-α inhibitors induce multiple molecular changes in psoriasis
title IL-17A and TNF-α inhibitors induce multiple molecular changes in psoriasis
title_full IL-17A and TNF-α inhibitors induce multiple molecular changes in psoriasis
title_fullStr IL-17A and TNF-α inhibitors induce multiple molecular changes in psoriasis
title_full_unstemmed IL-17A and TNF-α inhibitors induce multiple molecular changes in psoriasis
title_short IL-17A and TNF-α inhibitors induce multiple molecular changes in psoriasis
title_sort il-17a and tnf-α inhibitors induce multiple molecular changes in psoriasis
topic Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9723344/
https://www.ncbi.nlm.nih.gov/pubmed/36483564
http://dx.doi.org/10.3389/fimmu.2022.1015182
work_keys_str_mv AT dongqiang il17aandtnfainhibitorsinducemultiplemolecularchangesinpsoriasis
AT lidan il17aandtnfainhibitorsinducemultiplemolecularchangesinpsoriasis
AT xiebibo il17aandtnfainhibitorsinducemultiplemolecularchangesinpsoriasis
AT hulihua il17aandtnfainhibitorsinducemultiplemolecularchangesinpsoriasis
AT huangjia il17aandtnfainhibitorsinducemultiplemolecularchangesinpsoriasis
AT jiaxiaoxiao il17aandtnfainhibitorsinducemultiplemolecularchangesinpsoriasis
AT tangyanli il17aandtnfainhibitorsinducemultiplemolecularchangesinpsoriasis
AT liuganhong il17aandtnfainhibitorsinducemultiplemolecularchangesinpsoriasis
AT shenningning il17aandtnfainhibitorsinducemultiplemolecularchangesinpsoriasis
AT yuxiaobing il17aandtnfainhibitorsinducemultiplemolecularchangesinpsoriasis